Antibody-Dependent Cellular Phagocytosis

ADCP: The Covert MoA for Therapeutic Antibodies You Need to Know About (Part 2)

In our previous blog, we discussed antibody-dependent cellular phagocytosis (ADCP), a mechanism of action for therapeutic antibodies that is becoming increasingly appreciated. In vitro and in vivo experiments show that ADCP, a process where phagocytic cells ingest and lyse opsonized target cells, can clear lymphoma cells in the presence of therapeutic antibodies.  To harness the potential of these antibodies, researchers have sought to determine the factors that influence ADCP. What are 3 currently known factors that can impact ADCP? Phagocytic Effector Cell Subtype - Like mentioned above, ADCP is performed by phagocytic cell types that include monocytes, macrophages, [...]

ADCP: The Covert MoA for Therapeutic Antibodies You Need to Know About (Part 1)

Therapeutic antibodies can work through various mechanisms of action.  They can inhibit ligand-independent dimerization to prevent downstream survival and proliferation signaling pathways or induce apoptosis of target cells.  In addition, therapeutic antibodies can activate the immune system to drive antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to eliminate aberrant cells.  However, one lesser known mechanism mediated by the immune system that is also driven by these antibodies is antibody-dependent cellular phagocytosis (ADCP). In this blog, we will introduce ADCP and discuss the data that supports its role in the anti-tumoral effects of therapeutic antibodies. What is antibody-dependent [...]